Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 11/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617602 | 0.90 | TET2 (0.57) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL3619327 | 0.88 | MCL1 (0.53) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL3622423 | 0.86 | FABP4 (0.54) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL6409546 | 0.81 | TSHR (0.67) | HTTBRD4ALDH1A1MEN1KMT2A | |
| SCHEMBL6717132 | 0.80 | ACLY (0.54) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL6714571 | 0.79 | KDM4E (0.59) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL2372369 | 0.79 | GAA (0.56) | FABP4FABP5HTTNPSR1GAA | |
| SCHEMBL6710293 | 0.78 | ACLY (0.57) | FABP4FABP5MEN1KMT2AFFAR1 | |
| SCHEMBL6712639 | 0.78 | IDH1 (0.54) | FABP4FABP5MEN1PKMKMT2A | |
| SCHEMBL12190260 | 0.76 | GAA (0.56) | FABP4FABP5HTTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| CN-101402601-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes | BIOVITRUM AB PUBL (SE) | 2009-04-08 | — | — | CN | disclosed |
| CN-100457726-C | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | CAMBRIDGE BIOTECHNOLOGY LTD (SE) | 2009-02-04 | — | — | CN | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| CN-1800185-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. | BIOVITRUM AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | FABP4 13/4885FABP5 437/4885HTT 1789/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | FABP4 14/4885FABP5 479/4885HTT 1365/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | FABP4 66/4885FABP5 868/4885HTT 816/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | FABP4 14/4885FABP5 479/4885HTT 1365/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | FABP4 13/4885FABP5 437/4885HTT 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.